Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
about
Hepatocellular carcinoma: Where there is unmet needOleanolic acid suppresses aerobic glycolysis in cancer cells by switching pyruvate kinase type M isoformsSensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell CulturesCD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment.Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinomaPGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression.Inhibitory effect of ethanol extract of Ocimum sanctum on osteopontin mediated metastasis of NCI-H460 non-small cell lung cancer cells.FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cellsMultiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin.Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells.Molecular mechanism of cholangiocarcinoma carcinogenesis.Clinical relevance of autophagic therapy in cancer: Investigating the current trends, challenges, and future prospects.Signaling pathways as therapeutic targets in biliary tract cancer.Decreased ARID1A expression facilitates cell proliferation and inhibits 5-fluorouracil-induced apoptosis in colorectal carcinoma.Emerging molecular therapeutic targets for cholangiocarcinoma.Knockdown of Sall4 inhibits intrahepatic cholangiocarcinoma cell migration and invasion in ICC-9810 cells.Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss.Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis.A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway.Mechanistic insights of O-GlcNAcylation that promote progression of cholangiocarcinoma cells via nuclear translocation of NF-κB.Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis.Molecular mechanisms driving cholangiocarcinoma invasiveness: an overview.Progranulin modulates cholangiocarcinoma cell proliferation, apoptosis, and motility via the PI3K/pAkt pathway.Suppression of 14-3-3ζ in cholangiocarcinoma cells inhibits proliferation through attenuated Akt activity, enhancing chemosensitivity to gemcitabine.Gadd45β silencing impaired viability and metastatic phenotypes in cholangiocarcinoma cells by modulating the EMT pathway.Establishment of cholangiocarcinoma cell lines from patients in the endemic area of liver fluke infection in Thailand.TRIM24 is upregulated in human gastric cancer and promotes gastric cancer cell growth and chemoresistance.Inhibition of endothelial nitric oxide synthase in cholangiocarcinoma cell lines - a new strategy for therapy.Targeting cholangiocarcinoma.Reciprocal expression of p-AMPKa and p-S6 is strongly associated with the prognosis of gastric cancer.Increased EphB2 expression predicts cholangiocarcinoma metastasis.Inhibition of miR-10a-5p suppresses cholangiocarcinoma cell growth through downregulation of Akt pathway
P2860
Q28084046-82FA2B92-0AC0-4CFC-8D78-7311BB36B8DAQ28540878-FA684B49-69D3-4D4C-9482-4713F084F94AQ28550991-7EA910E9-2B58-46ED-BC03-E0D37AEF0BC9Q30378139-CF0EAC6E-1D06-47E7-A566-9F4B01317252Q33757003-17EC796E-A773-4821-A5DC-99C19F4EF235Q34420486-609E77F9-81D7-49EF-A224-D9079E10FCB8Q35366515-35111D01-C4D3-4E35-B353-BF869D9907EFQ35742526-08F3CF28-55C8-42BC-AD3E-4AC0ECE91E9AQ35890732-77E5AC9E-C62D-4B00-A0EC-35E66398D562Q37709171-FEA86A17-7873-4519-A181-CB717AF52495Q38217475-9D590708-07EF-41D5-82D2-E1CC5033BE16Q38689955-A01C5EA3-0357-4DA9-AB07-1BD6BB57360FQ38747573-C081E775-8248-45F2-8597-5C252A5F75D9Q38994522-7D94161F-66A9-4706-AF1C-8A89A6FF2D6AQ39227356-B14862AB-AC79-46DE-B159-1A19B6DDEF8CQ40976297-ABAE0771-F370-49AB-892C-A28AF297EA04Q41113380-CE37E5C3-2F9E-43B7-AC28-B4F1DD7F79BAQ41854656-5175F686-7009-4FE8-A41D-5D5B933E165DQ42012788-DBCDE35D-CA5D-42F1-9303-8456EC60C0ABQ42134504-86716036-8829-455A-AD2B-408E093C2F6FQ47550861-2C316019-6049-49D7-9922-2696BEF8EE8BQ47603972-32812766-32B0-4421-A25D-A29DF6911527Q49229992-FC8EDD97-4B53-41A8-9C92-71AB167AFBC6Q49234410-D3416423-969D-4D63-B201-950A531C7555Q49705802-DAF9D648-7F4F-493C-BF77-4663DDEF4512Q50128422-20FA1CCE-1FBD-4920-B4A6-4C98CB134E7BQ51003814-159B8E72-6AC4-499D-8322-32A0E0CEB760Q52597485-0D3B2147-EE21-4527-9F29-027E3CDC8FBCQ52757760-9735D7AB-424E-4209-9740-F5FFCA31B65EQ53293550-1CFF1F85-F5E8-45EE-9EBD-E541E3AF17FBQ54338851-F762B0C6-895D-4DE4-911F-4B3F9F5AE913Q58565330-71936610-B07E-439F-84AA-BB9923EFC033
P2860
Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Increased activation of PI3K/A ...... possible therapeutic strategy.
@en
Increased activation of PI3K/A ...... possible therapeutic strategy.
@nl
type
label
Increased activation of PI3K/A ...... possible therapeutic strategy.
@en
Increased activation of PI3K/A ...... possible therapeutic strategy.
@nl
prefLabel
Increased activation of PI3K/A ...... possible therapeutic strategy.
@en
Increased activation of PI3K/A ...... possible therapeutic strategy.
@nl
P2093
P2860
P1433
P1476
Increased activation of PI3K/A ...... possible therapeutic strategy.
@en
P2093
Anchalee Techasen
Anucha Puapairoj
Gregory J Riggins
Hasaya Dokduang
Nisana Namwat
Supak Yothaisong
Vajarabhongsa Bhudhisawasdi
P2860
P2888
P304
P356
10.1007/S13277-013-0945-2
P577
2013-07-06T00:00:00Z